An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease

Nature Medicine

Volumn 20, Issue 12, 2014, Pages 1464-1471

  Kikuchi, Ryosuke ^a,b   Nakamura, Kazuto ^a   MacLauchlan, Susan ^a   Ngo, Doan Thi Minh ^a   Shimizu, Ippei ^a   Fuster, Jose Javier ^a   Katanasaka, Yasufumi ^a   Yoshida, Sumiko ^a   Qiu, Yan ^c   Yamaguchi, Terry P ^d   Matsushita, Tadashi ^b   Murohara, Toyoaki ^e   Gokce, Noyan ^a   Bates, David O ^c,f   Hamburg, Naomi M ^a   Walsh, Kenneth ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; SFRP5 PROTEIN, MOUSE; SIGNAL PEPTIDE; VASCULOTROPIN A; WNT PROTEIN; WNT5A PROTEIN, MOUSE;

ANGIOGENESIS; ANIMAL; COLLATERAL CIRCULATION; DISEASE MODEL; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; MOUSE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; COLLATERAL CIRCULATION; DISEASE MODELS, ANIMAL; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL ARTERIAL DISEASE; PROTEIN ISOFORMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WNT PROTEINS;

EID: 84961290875     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3703     Document Type: Article

References (32)

1. Blann, A.D. et al. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or type II diabetes. Clin. Sci. (Lond.) 102, 187-194 (2002).
2. Findley, C.M., Mitchell, R.G., Duscha, B.D., Annex, B.H. & Kontos, C.D. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. J. Am. Coll. Cardiol. 52, 387-393 (2008).
3. Murray, C.J. et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2197-2223 (2012).
4. Hamburg, N.M. & Balady, G.J. Exercise rehabilitation in peripheral artery disease: functional impact and mechanisms of benefits. Circulation 123, 87-97 (2011).
5. Anderson, P.L. et al. Understanding trends in inpatient surgical volume: vascular interventions, 1980-2000. J. Vasc. Surg. 39, 1200-1208 (2004).
6. Go, A.S. et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 127, e6-e245 (2013).
7. Duscha, B.D. et al. Angiogenesis in skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patients. Arterioscler. Thromb. Vasc. Biol. 31, 2742-2748 (2011).
8. Carmeliet, P. & Jain, R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307 (2011).
9. Makin, A.J., Chung, N.A., Silverman, S.H. & Lip, G.Y. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis? Clin. Sci. (Lond.) 104, 397-404 (2003).
10. Mäkinen, K. et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol. Ther. 6, 127-133 (2002).
11. Rajagopalan, S. et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108, 1933-1938 (2003).
12. Bates, D.O. et al. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin. Cancer Res. 18, 6384-6391 (2012).
13. Kawamura, H., Li, X., Harper, S.J., Bates, D.O. & Claesson-Welsh, L. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Res. 68, 4683-4692 (2008).
14. Bates, D.O. et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 62, 4123-4131 (2002).
15. Harper, S.J. & Bates, D.O. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat. Rev. Cancer 8, 880-887 (2008).
16. Cébe Suarez, S. et al. A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell. Mol. Life Sci. 63, 2067-2077 (2006).
17. Jones, W.S. et al. Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training. Vasc. Med. 17, 94-100 (2012).
18. Dokun, A.O. & Annex, B.H. The VEGF165b "ICE-o-form" puts a chill on the VEGF story. Circ. Res. 109, 246-247 (2011).
19. Eswarappa, S.M. et al. Programmed translational readthrough generates antiangiogenic VEGF-Ax. Cell 157, 1605-1618 (2014).
20. McDermott, M.M. et al. Elevated levels of inflammation, d-dimer, and homocysteine are associated with adverse calf muscle characteristics and reduced calf strength in peripheral arterial disease. J. Am. Coll. Cardiol. 50, 897-905 (2007).
21. Vidula, H. et al. Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. Ann. Intern. Med. 148, 85-93 (2008).
22. Stefater, J.A. III et al. Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells. Nature 474, 511-515 (2011).
23. Kendall, R.L. & Thomas, K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA 90, 10705-10709 (1993).
24. Tischer, E. et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266, 11947-11954 (1991).
25. Ouchi, N. et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science 329, 454-457 (2010).
26. Marso, S.P. & Hiatt, W.R. Peripheral arterial disease in patients with diabetes. J. Am. Coll. Cardiol. 47, 921-929 (2006).
27. Schiekofer, S., Galasso, G., Sato, K., Kraus, B.J. & Walsh, K. Impaired revascularization in a mouse model of type 2 diabetes is associated with dysregulation of a complex angiogenic-regulatory network. Arterioscler. Thromb. Vasc. Biol. 25, 1603-1609 (2005).
28. Ho, H.Y. et al. Wnt5a-Ror-Dishevelled signaling constitutes a core developmental pathway that controls tissue morphogenesis. Proc. Natl. Acad. Sci. USA 109, 4044-4051 (2012).
29. Merdzhanova, G. et al. The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo. Oncogene 29, 5392-5403 (2010).
30. Aboyans, V. et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation 126, 2890-2909 (2012).
31. Ouchi, N. et al. Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J. Biol. Chem. 283, 32802-32811 (2008).
32. Kikuchi, R. et al. Pitavastatin-induced angiogenesis and arteriogenesis is mediated by Notch1 in a murine hind limb ischemia model without induction of VEGF. Lab. Invest. 91, 691-703 (2011).